CEO Amber Salzman walks us through the science, which allows the company to dial up or dial down genes of interest rather than making a cut into the DNA. They have dosed patients with FSHD, a type of muscular dystrophy, and have ASGCT presentations looking at other indications like Friedreich's ataxia, a type of Alzheimer's, and DMD. Coverage brought to you by

She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient...